BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that its Board of Directors has authorized the repurchase of up to $50 million of its outstanding shares of common stock in order to return value to its shareholders.
